Deconvolution of malignant pleural effusions immune landscape unravels a novel macrophage signature associated with worse clinical outcome in lung adenocarcinoma patients

BACKGROUND: Immune checkpoint inhibitors are still unable to provide clinical benefit to the large majority of non-small cell lung cancer (NSCLC) patients. A deeper characterization of the tumor immune microenvironment (TIME) is expected to shed light on the mechanisms of cancer immune evasion and r...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruschini, Sara, Pallocca, Matteo, Sperandio, Eleonora, D’Ambrosio, Lorenzo, Ascenzi, Francesca, De Vitis, Claudia, Salvati, Valentina, Esposito, Antonella, Di Martino, Simona, De Nicola, Francesca, Paolini, Francesca, Fattore, Luigi, Alessandrini, Gabriele, Facciolo, Francesco, Foddai, Maria Laura, Bassi, Massimiliano, Venuta, Federico, D’Ascanio, Michela, Ricci, Alberto, D’ Andrilli, Antonio, Napoli, Christian, Aurisicchio, Luigi, Fanciulli, Maurizio, Rendina, Erino Angelo, Ciliberto, Gennaro, Mancini, Rita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119185/
https://www.ncbi.nlm.nih.gov/pubmed/35584864
http://dx.doi.org/10.1136/jitc-2021-004239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119185/
https://www.ncbi.nlm.nih.gov/pubmed/35584864
http://dx.doi.org/10.1136/jitc-2021-004239

Ejemplares similares